The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy
Open accessAbstract
Currently, major concerns about the safety and efficacy of RNA interference (RNAi)-based bone anabolic strategies still exist because of the lack of direct osteoblast-specific delivery systems for osteogenic siRNAs. Here we screened the aptamer CH6 by cell-SELEX, specifically targeting both rat and human osteoblasts, and then we developed CH6 aptamer–functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domain-containing family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA). Our results showed that CH6 facilitated in vitro osteoblast-selective uptake of Plekho1 siRNA, mainly via macropinocytosis, and boosted in vivo osteoblast-specific Plekho1 gene silencing, which promoted bone formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties in both osteopenic and healthy rodents. These results indicate that osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Self-citationDevelopment of DNA aptamers using Cell-SELEX
Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918
Self-citationNovina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 724
Macropinocytosis: an endocytic pathway for internalising large gulps
Lim, J. P., & Gleeson, P. A. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2011.20 · Cited by 715
The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls
Vercauteren, D., Vandenbroucke, R. E., Jones, A. T., Rejman, J., Demeester, J., De Smedt, S. C., Sanders, N. N., & Braeckmans, K. (2010) · Molecular Therapy · doi:10.1038/mt.2009.281 · Cited by 689
miR-214 targets ATF4 to inhibit bone formation
Wang, X., Guo, B., Li, Q., Peng, J., Yang, Z., Wang, A., Li, D., Hou, Z., Lv, K., Kan, G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3026 · Cited by 559
Self-citationMui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy
Zhang, G., Guo, B., Wu, H., Tang, T., Zhang, B.-T., Zheng, L., He, Y., Yang, Z., Pan, X., Chow, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2617 · Cited by 413
Self-citationOsteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation
Lotinun, S., Kiviranta, R., Matsubara, T., Alzate, J. A., Neff, L., Lüth, A., Koskivirta, I., Kleuser, B., Vacher, J., Vuorio, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64840 · Cited by 328
Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., BouFakhreddine, S., Holohan, T. V., & Schaub, R. G. (2007) · Circulation · doi:10.1161/circulationaha.107.724864 · Cited by 286
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
Zamboni, W. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1895 · Cited by 234
Advances in lipid nanoparticles for siRNA delivery
Tam, Y., Chen, S., & Cullis, P. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5030498 · Cited by 229
Bone-targeting macromolecular therapeutics
WANG, D., MILLER, S., KOPECKOVA, P., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.011 · Cited by 203
Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1
Lu, K., Yin, X., Weng, T., Xi, S., Li, L., Xing, G., Cheng, X., Yang, X., Zhang, L., & He, F. (2008) · Nature Cell Biology · doi:10.1038/ncb1760 · Cited by 168
Self-citationYingjie, H., Ge, Z., Yisheng, W., Ling, Q., Hung, W. Y., Kwoksui, L., & Fuxing, P. (2007) · Bone · doi:10.1016/j.bone.2007.06.006 · Cited by 163
Pentosidine Effects on Human Osteoblasts in Vitro
Sanguineti, R., Storace, D., Monacelli, F., Federici, A., & Odetti, P. R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.044 · Cited by 140
Rockey, W. M., Hernandez, F. J., Huang, S.-Y., Cao, S., Howell, C. A., Thomas, G. S., Liu, X. Y., Lapteva, N., Spencer, D. M., Mcnamara, J. O., et al. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0313 · Cited by 139
Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine
Ye, M., Hu, J. J., Peng, M., Liu, J., Liu, J., Liu, H., Zhao, X., & Tan, W. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033341 · Cited by 136
Self-citationŠuša, M., Luong-Nguyen, N.-H., Cappellen, D., Zamurovic, N., & Gamse, R. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-6 · Cited by 114
Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes
Auguste, D. T., Furman, K., WONG, A., Fuller, J. E., Armes, S. P., Deming, T. J., & Langer, R. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.06.004 · Cited by 106
Herman, S., Müller, R. B., Krönke, G., Zwerina, J., Redlich, K., Hueber, A. J., Gelse, H., Neumann, E., Müller‐Ladner, U., & Schett, G. A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23943 · Cited by 102
Dynamin 2 mediates fluid-phase micropinocytosis in epithelial cells
Cao, H., Chen, J., Awoniyi, M., Henley, J. R., & McNiven, M. A. (2007) · Journal of Cell Science · doi:10.1242/jcs.010686 · Cited by 92
RNA Interference Technologies and Therapeutics: From Basic Research to Products
López‐Fraga, M., Martínez, T., & Jiménez, A. (2009) · BioDrugs · doi:10.2165/11318190-000000000-00000 · Cited by 70
RNA therapeutics targeting osteoclast-mediated excessive bone resorption
Wang, Y., & Grainger, D. W. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.09.002 · Cited by 45
Involvement of FcR in signal transduction of osteoclast-associated receptor (OSCAR)
Ishikawa, S., Arase, N., Suenaga, T., Saita, Y., Noda, M., Kuriyama, T., Arase, H., & Saito, T. (2004) · International Immunology · doi:10.1093/intimm/dxh103 · Cited by 45
Guo, B., Zhang, B., Zheng, L., Tang, T., Liu, J., Wu, H., Yang, Z., Peng, S., He, X., Zhang, H., et al. (2013) · Bone · doi:10.1016/j.bone.2013.11.007 · Cited by 36
Self-citationBisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration
Wang, G., Kucharski, C., Lin, X., & Uludağ, H. (2010) · Journal of drug targeting · doi:10.3109/10611861003622560 · Cited by 31
Kishimoto, Y. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh395 · Cited by 18
Fukushima, N., Hiraoka, K., Shirachi, I., Kojima, M., & Nagata, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.036 · Cited by 17
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Analysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
Recent Advances in Aptamer Discovery and Applications
Zhang, Y., Lai, B. S., & Juhas, M. (2019) · Molecules · doi:10.3390/molecules24050941 · Cited by 663
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Self-citationOsteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., He, X., Cheung, H. Y.-S., Xu, L., Lu, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10872 · Cited by 588
Self-citation
Metadata
- Authors
- Liang, C., Guo, B., Wu, H., Shao, N., Li, D., Liu, J., Dang, L., Wang, C., Li, H., Li, S., Lau, W. K., Cao, Y., Yang, Z., Lu, C., He, X., Au, D. W. T., Pan, X., Zhang, B.-T., Lu, C., Zhang, H., Yue, K., Qian, A., Shang, P., Xu, J., Xiao, L., Bian, Z., Tan, W., Liang, Z., He, F., Zhang, L., Lu, A., & Zhang, G.
- Venue
- Nature Medicine
- Published
- 2015-02-09
- Volume
- 21
- Issue
- 3
- Pages
- 288-294
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2047103966
- Cited by
- 354
- References
- 32
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.